Introduction {#s1}
============

Some invertebrate and vertebrate dopamine (DA) receptor types demonstrate a strong phylogenetic relationship that is reflected in an apparent conservation of common functional properties [@pone.0026809-Mustard1], [@pone.0026809-Mcdonald1], [@pone.0026809-Missale1]. For example, D2-like DA receptors in arthropods exhibit significant homology in primary amino acid sequence with vertebrate D2-like dopamine receptors [@pone.0026809-Hearn1], [@pone.0026809-Beggs1], [@pone.0026809-Clark1] and in arthropods, as in vertebrates, activation of D2-like receptors generally inhibits adenylyl cyclase activity leading to a reduction in intracellular levels of cAMP [@pone.0026809-Mustard1], [@pone.0026809-Missale1]. However, phylogenetic analyses indicate that at least one DA receptor type may be specific to invertebrate species [@pone.0026809-Mustard1], [@pone.0026809-Humphries1]. The presence of this 'invertebrate-type' DA receptor ([Figure 1](#pone-0026809-g001){ref-type="fig"}) raises a number of interesting questions about the origin, function and role of this receptor protein in the invertebrate nervous system.

![Phylogram of selected arthropod amine receptor sequences.\
A phylogenetic analysis showing known invertebrate-type DA receptors and α-adrenergic-like OA receptors and their relationship to other DA, OA and TA receptors from *Apis mellifera* and *Drosophila melanogaster*. The honey bee rhodopsin protein is used as an outlier. Conserved regions of receptor protein sequences were aligned using ClustalW2 software (version 2.0.10) using the default settings (<http://ww.ebi.ac.uk/Tools/clustalw2/>). Phylograms were prepared as described in [@pone.0026809-Beggs2] by a 1000 trial N-J bootstrap analysis, and using ClustalX software (version 2.0). Resulting bootstrap scores are displayed on selected nodes as percentages values, if greater than 50%.](pone.0026809.g001){#pone-0026809-g001}

The first of these invertebrate-type DA receptors to be functionally described was the *Drosophila* DAMB/Dop99B receptor [@pone.0026809-Han1], [@pone.0026809-Feng1]. Orthologues of this receptor have subsequently been described in several arthropod species [@pone.0026809-Ono1], [@pone.0026809-Clark2], [@pone.0026809-Gerber1], [@pone.0026809-Ohta1], including in honey bees (*Am*DOP2, [@pone.0026809-Humphries1]). All of the invertebrate-type DA receptors examined so far have been found to be positively coupled to adenylyl cyclase and hence are often described as D1-like DA receptors [@pone.0026809-Mustard1]. Interestingly, stimulation of cells expressing the DAMB/Dop99B receptor with DA also induces a rapid, transient increase in intracellular calcium (Ca^2+^) levels [@pone.0026809-Feng1], [@pone.0026809-Han2], [@pone.0026809-Reale1]. However, this property has yet to be demonstrated in other invertebrate-type DA receptors.

One intriguing feature of invertebrate-type DA receptors is that their primary amino acid sequences, when compared to other invertebrate biogenic amine receptors, show highest homology to an octopamine (OA) receptor type [@pone.0026809-Mustard1], [@pone.0026809-Humphries1], [@pone.0026809-Balfanz1], [@pone.0026809-Hauser1], [@pone.0026809-Hauser2] described as being 'α-adrenergic-like' [@pone.0026809-Evans1]. The first α-adrenergic-like OA receptor was described in a pond snail [@pone.0026809-Gerhardt1] and orthologues that have been identified subsequently include the *Drosophila* OAMB receptor [@pone.0026809-Han2], honey bee *Am*OA1 receptor [@pone.0026809-Grohmann1], cockroach Pa oa~1~ receptor [@pone.0026809-Bischof1] and silkworm *Bm*OAR1 [@pone.0026809-Ohtani1] receptor. Functional studies of cells expressing α-adrenergic-like OA receptor orthologues have consistently found that activation by OA results in a rapid, transient rise in intracellular Ca^2+^ concentrations, but also an increase in intracellular levels of cAMP [@pone.0026809-Han2], [@pone.0026809-Balfanz1], [@pone.0026809-Gerhardt1], [@pone.0026809-Grohmann1], [@pone.0026809-Bischof1], [@pone.0026809-Ohtani1]. Interestingly, depletion of intracellular Ca^2+^ with BAPTA-AM was found to have no significant effect on cAMP signaling mediated either, via DAMB/Dop99B receptors [@pone.0026809-Reale1] or Pa oa~1~-receptors [@pone.0026809-Bischof1] indicating that both of these receptor types mediate their effects on cAMP via a pathway independent of the Ca^2+^ signaling pathway. However this concept of pathway independence has also been challenged [@pone.0026809-Balfanz1], [@pone.0026809-Evans1], [@pone.0026809-Grohmann1], with increases in cAMP levels suggested to be the result of Ca^2+^-induced adenylyl cyclase activity.

Phylogenetic models have indicated that the invertebrate-type DA receptors and the α-adrenergic-like OA receptors are immediate paralogs [@pone.0026809-Hauser1], [@pone.0026809-Hauser2]. However, as such models may contain inherent weaknesses in their ability to discern distant evolutionary relationships correctly [@pone.0026809-Vernier1], evidence at a functional level is required also to confirm the existence of such relationships. In this study we examined the functional and pharmacological properties of the invertebrate-type DA receptor from honey bee, *Am*DOP2, and the honey bee α-adrenergic-like octopamine receptor, *Am*OA1, as representative examples of each of the two receptor types ([Figure 1](#pone-0026809-g001){ref-type="fig"}). Analysis of these two receptors in parallel enabled us to test predictions arising from phylogenetic modelling.

Our study provides evidence that agonist activation of either, *Am*DOP2 or *Am*OA1 receptors results in stimulation of cAMP and Ca^2+^ signaling pathways, and that these pathways are activated independently upstream of PLCβ activity. We also show that there are marked similarities in the pharmacological properties of these two receptor types, a finding supported further by comparisons with other related receptor types. The homology we find in the functional and pharmacological properties of *Am*DOP2 and *Am*OA1 receptors supports the phylogenetic model of these receptor genes as being immediate paralogs.

Results {#s2}
=======

*Am*DOP2 receptors couple to Ca^2+^ signaling pathways {#s2a}
------------------------------------------------------

We found that exposure of *Am*DOP2-expressing HEK293 cells to 1 µM DA initiated a rapid increase in intracellular Ca^2+^ levels, with maximum response amplitude occurring 15 to 20 seconds post injection ([Figure 2A](#pone-0026809-g002){ref-type="fig"}). Exposure of *Am*DOP2-expressing cells to 1 µM OA also initiated a Ca^2+^ response, but responses to this amine were smaller in amplitude and slower to reach peak levels (approximately 25 s) than responses to DA ([Figure 2A](#pone-0026809-g002){ref-type="fig"}). Exposure to 1 µM tyramine (TA) had no observable effect on *Am*DOP2-expressing cells ([Figure 2A](#pone-0026809-g002){ref-type="fig"}). Control cells expressing the β-Gal reporter protein showed no Ca^2+^ response to DA, OA or TA (data not shown). The Ca^2+^ response of *Am*DOP2-expressing HEK293 cells to DA was dose-dependent ([Figure 2C](#pone-0026809-g002){ref-type="fig"}).

![Agonist-induced changes in intracellular Ca^2+^ levels in HEK293 cells expressing either *Am*DOP2 receptors or *Am*OA1 receptors.\
Cells were preloaded with the \[Ca^2+^\]~I~ reporter dye Fluo-4 and monitored for agonist-induced changes in fluorescence signal. The data shown are from a single trial and are representative of results obtained from 3 independent trials at each agonist concentration (with two internal replicates per trial), and over 30 trials using 1 µM. Changes in fluorescence examined in the following: (A) *Am*DOP2-expressing HEK293 cells exposed to 1 µM DA, OA or TA; (B) *Am*OA1-expressing HEK293 cells exposed to 1 µM DA, OA or TA; (C) *Am*DOP2-expressing HEK293 cells exposed to DA at the concentrations indicated to the right of [Figure 1C](#pone-0026809-g001){ref-type="fig"}; (D) *Am*OA1-expressing HEK293 cells exposed to OA at the concentrations indicated to the right of [Figure 1D](#pone-0026809-g001){ref-type="fig"}.](pone.0026809.g002){#pone-0026809-g002}

For comparison we also examined *Am*OA1-expressing HEK293 cells. *Am*OA1-mediated Ca^2+^ signaling has been identified previously in HEK293 cells using single cell monitoring [@pone.0026809-Grohmann1] and we found also that *Am*OA1-expressing HEK293 cells showed a rapid increase in intracellular Ca^2+^ levels in response to 1 µM OA ([Figure 2B](#pone-0026809-g002){ref-type="fig"}). Responses to 1 µM OA peaked approximately 15 to 20 seconds post injection and then declined steadily. *Am*OA1-expressing HEK293 cells also showed a smaller amplitude response to 1 µM TA, but no response to 1 µM DA ([Figure 2B](#pone-0026809-g002){ref-type="fig"}). The Ca^2+^ response of *Am*OA-expressing cells to OA was dose-dependent ([Figure 2D](#pone-0026809-g002){ref-type="fig"}).

*Am*DOP2 receptors and *Am*OA1 receptors couple to cAMP signaling via a PLCβ-independent pathway {#s2b}
------------------------------------------------------------------------------------------------

To determine if *Am*DOP2 and *Am*OA1 receptors are coupled to intracellular Ca^2+^ signaling via a PLCβ-mediated pathway we investigated the effect of the PLC inhibitor, edelfosine [@pone.0026809-Powis1]. Using HEK293 cells expressing either *Am*DOP2 receptors ([Figure 3A](#pone-0026809-g003){ref-type="fig"}) or *Am*OA1 receptors ([Figure 3B](#pone-0026809-g003){ref-type="fig"}), we found that treatment with 10 µM edelfosine significantly reduced the amplitude of Ca^2+^ signals elicited by 1 µM DA and 1 µM OA, respectively. These results indicate that PLCβ activity is part of the signaling pathway that leads to increases in intracellular Ca^2+^ levels resulting from *Am*DOP2- or *Am*OA1-receptor activation.

![PLCβ activity is required for *Am*DOP2- and *Am*OA1-mediated intracellular Ca^2+^ signaling.\
Treatment with edelfosine (edlf) was found to inhibit *Am*DOP2 (*P*\<0.0001) and *Am*OA1 (*P* = 0.0002) mediated Ca^2+^ signaling. HEK293 cells expressing either *Am*DOP2 receptors (A) or *Am*OA1 receptors (B) were loaded with the intracellular Ca^2+^ reporter dye Fluo-4, with or without the inclusion of 10 µM edelfosine (Edlf) in the loading buffer. Cells were subsequently exposed to a 1 µM concentration of agonist and the maximal ΔF/F~b~ in following 50 s period determined. Data are normalized to the percentage response observed in cells not treated with edelfosine, and are the result of three independent experiments, with two internal replicates per experiment. Error bars represent the SEM. Statistical significance was determined using Student\'s two-tailed *t* tests.](pone.0026809.g003){#pone-0026809-g003}

To determine whether *Am*DOP2- and/or *Am*OA1-mediated increases in intracellular cAMP levels require PLCβ activity we tested the effects of edelfosine on responses to DA and OA in *Am*DOP2- and *Am*OA1-expressing HEK293 cells, respectively. We found that in contrast to its effects on Ca^2+^ signaling, treatment with 10 µM edelfosine had no significant effect on agonist-induced changes in levels of cAMP mediated by *Am*DOP2 or by *Am*OA1 ([Figures 4A,B](#pone-0026809-g004){ref-type="fig"}). These results suggest that *Am*DOP2 receptors and *Am*OA1 receptors couple to cAMP signaling via a PLCβ-independent pathway.

![PLCβ activity is not required for *Am*DOP2- or *Am*OA1-mediated intracellular cAMP signaling.\
Treatment with edelfosine (edlf) had no significant effect on \[cAMP\]~i~ signaling mediated via *Am*DOP2 receptors (*P* = 0.9751), or via *Am*OA1 receptors (*P* = 0.2224). HEK293 cells were co-transfected with expression constructs for either the *Am*DOP2 receptor (A) or *Am*OA1 receptor (B), and a CRE-luciferase reporter construct. Cells were treated with either 1 µM agonist (DA and OA respectively) or 1 µM agonist and 10 µM edelfosine (edlf). Data are normalized to the response observed in cells not treated with edelfosine, and the mean of three independent experiments within which, each treatment was tested twice. Error bars represent the SEM. Statistical significance was determined using Student\'s two-tailed *t* tests.](pone.0026809.g004){#pone-0026809-g004}

*Am*DOP2 and *Am*OA1 receptors have similar pharmacological properties {#s2c}
----------------------------------------------------------------------

To compare the pharmacological profiles of *Am*DOP2 and *Am*OA1 receptors we tested four amine-receptor antagonists: *cis*-(Z)-flupentixol, spiperone, mianserin and epinastine. *Cis*-(Z)-flupentixol and spiperone have been used extensively in insects as dopamine-receptor antagonists, whereas mianserin and epinastine are most commonly used in insects as octopamine receptor antagonists (see [Discussion](#s3){ref-type="sec"}).

We began by investigating the effects of each of these compounds on cAMP responses generated through the activation of *Am*DOP2 receptors and *Am*OA1 receptors. Cells expressing *Am*DOP2 or *Am*OA1 receptors were exposed to 1 µM DA or 1 µM OA respectively, together with one of the four putative antagonists ([Figure 5](#pone-0026809-g005){ref-type="fig"}). We found that irrespective of whether cAMP responses were mediated via *Am*DOP2 receptors or via *Am*OA1 receptors they could be blocked in a dose-dependent way by all 4 antagonists ([Figure 5](#pone-0026809-g005){ref-type="fig"}). Next we tested the effect of a 10 µM concentration of each of these antagonists on *Am*DOP2- and *Am*OA1-mediated Ca^2+^ signals. Again we found that all four compounds acted as effective antagonists of responses mediated by *Am*DOP2 receptors, as well as by *Am*OA1 receptors ([Figure 6](#pone-0026809-g006){ref-type="fig"}).

![Effects of amine-receptor antagonists on cAMP responses mediated via *Am*DOP2 and *Am*OA1 receptors.\
HEK293 cells were co-transfected with expression constructs for either the *Am*DOP2 receptor (blue symbols) or *Am*OA1 receptor (red symbols) and a CRE-luciferase reporter construct. Cells were treated with 1 µM agonist (DA or OA respectively) or 1 µM agonist and either *cis*-(Z)-flupentixol (A), spiperone (B), mianserin (C) or epinastine (D), at a range of concentrations indicated in the figure. Due to evidence of significant cell toxicity, *cis*-(Z)-flupentixol was not tested at a concentration higher than 10 µM. Data are normalized to the response observed in cells treated with agonist alone (not shown), and are the result of two independent experiments within which, each treatment was tested twice. Error bars (estimated SEM) are included to provide an indication of consistency between experiments. Dose response curves were determined by non-linear regression using GraphPad Prism software for Macintosh version 5.0b.](pone.0026809.g005){#pone-0026809-g005}

![Effect of antagonists on *Am*DOP2- and *Am*OA1-mediated intracellular Ca^2+^ signaling.\
HEK293 cells expressing either *Am*DOP2 receptors (A) or *Am*OA1 receptors (B) were loaded with the intracellular Ca^2+^ reporter dye Fluo-4 and exposed to 1 µM agonist (DA and OA respectively), or 1 µM agonist and either 10 µM cis-(Z)-flupentixol, spiperone, mianserin or epinastine and the maximal ΔF/F~b~ over following 50 second period determined. Data are normalized to the response observed in cells treated with agonist alone, and are the result of three independent experiments with two internal replicates per experiment. Error bars represent the SEM. Statistical significance was determined using one-way ANOVA and Dunnett\'s multiple comparison test, with treatment with agonist alone used as the control column. F~4,10~ = 239.1, P\<0.0001 for (A); F~4,10~ = 35.95, P\<0.0001 for (B).](pone.0026809.g006){#pone-0026809-g006}

To assess further the specificity of the 4 antagonists, we examined their actions on changes in intracellular cAMP mediated via the honey bee dopamine receptors *Am*DOP1 [@pone.0026809-Blenau1] and *Am*DOP3 [@pone.0026809-Beggs1], and the honey bee tyramine receptor, *Am*TYR1 [@pone.0026809-Blenau2]. Our results are shown in [Figure 7](#pone-0026809-g007){ref-type="fig"} and summarized in [Table 1](#pone-0026809-t001){ref-type="table"}. We found that mianserin acted as a relatively weak antagonist on the *Am*TYR1 receptor and that spiperone, also in relatively high concentrations, blocked cAMP responses mediated via *Am*DOP1. Responses mediated via *Am*DOP3 receptors were not affected significantly by mianserin, epinastine, *cis*-(Z)-flupentixol or spiperone.

![Pharmacological profile of *Am*DOP1, *Am*DOP3 and *Am*TYR1 receptors.\
HEK293 cells were co-transfected with expression constructs for one of the following amine receptors, the *Am*DOP1 receptor (A, D, G, J), *Am*DOP3 receptor (B, E, H, K), or *Am*TYR1 receptor (C, F, I, L) and a CRE-luciferase reporter construct. Cells were treated with 1 µM agonist, or with 1 µM agonist together with one of the following antagonists: *cis*-(Z)-flupentixol (A, B, C), spiperone (D, E, F), mianserin (G, H, I) or epinastine (J, K, L) at concentrations indicated in each figure. For assaying the activity of *Am*DOP3 and *Am*TYR1 receptors, both of which reduce intracellular cAMP levels, basal cAMP levels in test cells were elevated by inclusion of a nonsaturating concentration of the adenylyl cyclase stimulant, forskolin (100 nM). Data are normalized to the percentage response observed in cells treated with agonist alone (not shown), and are the result of two independent experiments within which, each treatment was tested twice. Error bars represent the estimated SEM. Dose response curves were determined by non-linear regression using GraphPad Prism software for Macintosh version 5.0b, and displayed when the resulting curves were unambiguous.](pone.0026809.g007){#pone-0026809-g007}

10.1371/journal.pone.0026809.t001

###### Estimated IC~50~ values of antagonists on cAMP responses mediated via honeybee biogenic amine receptors.

![](pone.0026809.t001){#pone-0026809-t001-1}

  ANTAGONIST                        RECEPTOR                           
  -------------------------------- ---------- --------- ---- --------- -------
  ***cis*** **-(Z)-Flupentixol**       NS      0.3 µM    NS   1.3 µM     NS
  **Spiperone**                      90 µM     10.8 µM   NS   12.5 µM    NS
  **Mianserin**                        NS      0.4 µM    NS   4.1 µM    73 µM
  **Epinastine**                       NS      1.1 µM    NS   3.3 µM     NS

Estimated IC~50~ values were calculated by non-linear regression using GraphPad Prism software for Macintosh version 5.0b using data displayed in [Figures 5](#pone-0026809-g005){ref-type="fig"} and [7](#pone-0026809-g007){ref-type="fig"}. NS represents a finding of no significant antagonist activity.

Selectivity of epinastine {#s2d}
-------------------------

Analysis of putative ligand binding sites reveals only subtle differences between *Am*DOP1, *Am*DOP2 and *Am*OA1 ([Figure 8](#pone-0026809-g008){ref-type="fig"}). Three aromatic residues are completely conserved in TM6 (W285, F288 and F289; *Am*DOP1 numbering). Why then does the antihistamine, epinastine, bind both to *Am*DOP2 and *Am*OA1 but not to *Am*DOP1? A structural analysis of homology models reveals *Am*DOP2, *Am*OA1 and *Am*TYR1 possess a hydrophilic residue (E201, N243 and R192, respectively, yellow [Figure 8](#pone-0026809-g008){ref-type="fig"}) prior to TMV whereas *Am*DOP1 has a leucine residue (L188). The corresponding position (D186) has been previously shown to be important for histamine binding to H1 receptors (see [Discussion](#s3){ref-type="sec"}).

![Sequence alignment of *Am*DOP1, *Am*DOP2, *Am*OA1, AmTYR1, human H1 histamine receptor (NP_001091683.1), human β-adrenergic receptor (NP_000015.1).\
Residues highlighted in gray represent the transmembrane helices from the structure of the human β-adrenergic receptor (pdb2rh1), residues highlighted in cyan are those conserved in the GPCR family [@pone.0026809-Fiser1], the red aspartic acid is the highly conserved D107 (hHis numbering: Asp113 - HmB-Adr) on helix 3 (TMIII; residues not shown for I3).](pone.0026809.g008){#pone-0026809-g008}

Discussion {#s3}
==========

Phylogenetic analyses indicate that invertebrate-type DA receptors are more closely related to α-adrenergic-like OA receptors than to vertebrate D1-like receptors [@pone.0026809-Hauser1], [@pone.0026809-Hauser2], see [Figure 1](#pone-0026809-g001){ref-type="fig"}. However, while phylogenetic models have proven very useful for the reliable identification of conserved GPCR receptor ortholog families, limitations inherent in such models restrict their utility for confident identification of evolutionary relationships between GPCR receptors [@pone.0026809-Vernier1], [@pone.0026809-Baldauf1]. Direct comparison in this study of the functional properties of the invertebrate-type DA receptor, *Am*DOP2, and the α-adrenergic-like OA receptor, *Am*OA1, enabled us to determine whether the functional properties of these two receptor types are indeed conserved.

*Am*DOP2 and *Am*OA1 receptors exhibit similar functional properties {#s3a}
--------------------------------------------------------------------

Previous studies have shown that activation of the honey bee DA receptor, *Am*DOP2, leads to a rise in intracellular levels of cAMP [@pone.0026809-Humphries1], [@pone.0026809-Mustard2], [@pone.0026809-Beggs2], and our results indicate that this invertebrate-type DA receptor couples also to intracellular Ca^2+^ signaling pathways ([Figure 2](#pone-0026809-g002){ref-type="fig"}). The *Drosophila* ortholog of the *Am*DOP2 receptor (the DAMB/DopR99B receptor [@pone.0026809-Feng1], [@pone.0026809-Han1]) has been found to show similar properties [@pone.0026809-Feng1], [@pone.0026809-Han2], [@pone.0026809-Reale1]. For example, expressed in HEK293 cells, DopR99B/DAMB receptors respond to DA not only with an increase in intracellular cAMP, but also with a rapid, transient rise in intracellular Ca^2+^ levels [@pone.0026809-Han2], and activation of DAMB/DopR99B receptors expressed in *Xenopus* oocytes results in transient activation of an endogenous Ca^2+^-dependent chloride current [@pone.0026809-Feng1], [@pone.0026809-Reale1].

The ability to interact with both cAMP and Ca^2+^ signaling pathways has been reported also for several invertebrate α-adrenergic-like OA receptor orthologues [@pone.0026809-Bischof1], [@pone.0026809-Ohtani1], including the honey bee receptor, *Am*OA1 [@pone.0026809-Grohmann1]. However, in marked contrast to the invertebrate-type DA receptor, *Am*DOP2, and the adrenergic-like OA receptor, *Am*OA1, we could find no evidence that the honey bee DA receptors, *Am*DOP1 or *Am*DOP3, interact with calcium-signaling pathways, as well as with cAMP. This was true also for the honey bee tyramine receptor, *Am*Tyr1, a result consistent with the findings of Blenau et al. [@pone.0026809-Blenau2]. Thus, in terms of their coupling to second-messenger systems, the functional properties of *Am*DOP2 receptors appear to be more similar to those of *Am*OA1 receptors than to those of *Am*DOP1, *Am*DOP3 or *Am*Tyr1 receptors.

*Am*DOP2 receptors show independent coupling to two signaling pathways {#s3b}
----------------------------------------------------------------------

Previous studies have shown that depleting intracellular Ca^2+^ levels with BAPTA-AM has no significant effect on changes in intracellular cAMP mediated either via the *Drosophila* DA receptor, DAMB/DopR99B [@pone.0026809-Reale1], or the cockroach α-adrenergic-like OA receptor, Pa oa~1~ [@pone.0026809-Bischof1]. These results suggest that these receptor types mediate their effects on intracellular cAMP, independent of Ca^2+^ signaling [@pone.0026809-Reale1], [@pone.0026809-Bischof1]. However, this conclusion has been challenged with the alternative explanation that increases in intracellular cAMP levels are a secondary effect of receptor activation, resulting from receptor-mediated increases in intracellular Ca^2+^ inducing adenylyl cyclase activity [@pone.0026809-Balfanz1], [@pone.0026809-Grohmann1].

Studies of the Dop99B/DAMB receptor [@pone.0026809-Feng1], [@pone.0026809-Reale1] have suggested that this invertebrate-type DA receptor is most likely to be coupled to phosphoinositide metabolism via the activity of PLCβ, with receptor activation giving rise to rapid increases in intracellular Ca^2+^ levels. In an attempt to determine whether *Am*DOP2 and *Am*OA1 receptors couple to two independent signaling pathways, we tested the effect of the PLCβ-specific inhibitor edelfosine on responses mediated via *Am*DOP2 and *Am*OA1. Results showing that edelfosine treatment significantly reduces *Am*DOP2- and *Am*OA1-receptor-mediated Ca^2+^ signaling ([Figure 3](#pone-0026809-g003){ref-type="fig"}), indicate the involvement of PLCβ activity in the Ca^2+^ signals initiated by the activation of these receptors. Interestingly, *Am*DOP2- and *Am*OA1-receptor-mediated increases in intracellular levels of cAMP were not affected by edelfosine ([Figure 4](#pone-0026809-g004){ref-type="fig"}). While this result does not rule out the possibility that adenylyl cyclase activity is affected by changes in intracellular Ca^2+^ levels, it suggests that *Am*DOP2- and *Am*OA1-receptor-mediated cAMP signaling is not dependent on receptor-mediated changes in intracellular Ca^2+^.

It will be of considerable interest in the future to clarify the mechanism of G-protein coupling of *Am*DOP2 and *Am*OA1 receptors to cAMP- and Ca^2+^-mediated signaling, and the relative importance of these two signaling pathways *in vivo*. The coupling of the DAMB/Dop99B receptor to specific classes of heterotrimeric G proteins has been investigated in *Xenopus* oocytes [@pone.0026809-Reale1]. Unusually, it was found that cAMP signalling via this receptor was inhibited by pertussis toxin, suggesting coupling to the G~i/o~ class of G-proteins and signaling by G~βγ~ subunits. In contrast DAMB/Dop99B-mediated Ca^2+^ signaling was found not to be sensitive to pertussis toxin treatment nor to involve signaling via G~βγ~ subunits. These results were suggested to indicate that this receptor is able to couple to multiple G-protein effectors, potentially mediating its effects on Ca^2+^ by coupling to the G~q~ class of subunits [@pone.0026809-Reale1]. Interestingly, a study of the orthologous D~1αPan~ receptor in the spiny lobster found evidence for coupling to the G~s~ class of G-proteins, but neither the G~q~ or G~i/o~ classes [@pone.0026809-Clark2]. To date there have been no reports on the G-protein coupling of any member of the α-adrenergic-like OA receptors.

*Am*DOP2 and *Am*OA1 share similar pharmacological properties {#s3c}
-------------------------------------------------------------

GPCR receptors with a close evolutionary relationship are frequently found to display similarities in their pharmacological properties [@pone.0026809-Vernier1] and in the present study we found this to be true of *Am*DOP2 and *Am*OA1. Interestingly, c*is*-(Z)-flupentixol and spiperone, compounds generally used as dopamine receptor antagonists in insects [@pone.0026809-Mustard1], [@pone.0026809-Mustard2], as well as mianserin and epinastine, which are known to function as invertebrate OA receptor antagonists [@pone.0026809-Gerhardt1], [@pone.0026809-Ohtani1], [@pone.0026809-Roeder1], were all found to be effective blockers of *Am*DOP2 receptors, as well as *Am*OA1 receptors ([Figure 5](#pone-0026809-g005){ref-type="fig"}). Comparison of the estimated IC~50~ values ([Table 1](#pone-0026809-t001){ref-type="table"}) indicates that the rank order of potency of these antagonists on the *Am*DOP2 receptor is as follows: *cis*-(Z)-flupentixol≥mianserin\>epinastine\>spiperone, and on the *Am*OA1 receptor, *cis*-(Z)-flupentixol\>epinastine≥mianserin\>spiperone. All four compounds were also found to be highly effective at blocking *Am*DOP2- and *Am*OA1-mediated Ca^2+^ signaling ([Figure 6](#pone-0026809-g006){ref-type="fig"}). Indeed, our data suggest that spiperone, and to a lesser extent cis-(Z)-flupentixol, may be more potent blockers of Ca^2+^ signals mediated via *Am*OA1 and *Am*DOP2 than cAMP responses (compare [Figures 5](#pone-0026809-g005){ref-type="fig"} and [6](#pone-0026809-g006){ref-type="fig"}), however further analysis is required to confirm this finding. In contrast, we found that the same compounds were significantly less effective at blocking activation of the DA receptors, *Am*DOP1 and *Am*DOP3, and the tyramine receptor, *Am*TYR1 ([Table 1](#pone-0026809-t001){ref-type="table"} & [Figure 7](#pone-0026809-g007){ref-type="fig"}). Consistent with earlier studies [@pone.0026809-Mustard2], we found that spiperone exhibited significant antagonist activity on the D1-like DA receptor, *Am*DOP1 and we found in addition that mianserin blocked activity mediated via the *Am*TYR1 receptor. However, both antagonists were more effective on *Am*DOP2 and *Am*OA1 receptors than on *Am*DOP1, *Am*DOP3 or *Am*TYR1.

*Cis*-(Z)-flupentixol {#s3d}
---------------------

We were surprised by our finding that *cis*-(Z)-flupentixol had no significant antagonist activity on either, *Am*DOP1 or *Am*DOP3 receptors ([Figure 7](#pone-0026809-g007){ref-type="fig"}, [Table 1](#pone-0026809-t001){ref-type="table"}). This was unexpected because *cis*-(Z)-flupentixol has been found in earlier studies to be an effective *Am*DOP1 receptor antagonist (26,29) and is reported in the fruit fly to block *Dm*Dop1/dDA1 [@pone.0026809-Gotzes1], [@pone.0026809-Sugamori1], DAMB/Dop99B [@pone.0026809-Reale1] and DD2R [@pone.0026809-Hearn1]. It is reported also to be an effective blocker of the two D1-like DA receptors found in the silkworm [@pone.0026809-Ohta1], and a highly effective reverse agonist, not only of the honey bee *Am*DOP1 receptor [@pone.0026809-Mustard2], but also of the orthologous receptors in *Aplysia* (*Ap*Dop1) and *C. elegans* (dop-1) [@pone.0026809-Barbas1], [@pone.0026809-Sanyal1]. It is possible that our use of an indirect cAMP reporter system in this study contributed to our inability to detect antagonist activity of *cis*-(Z)-flupentixol on *Am*DOP1. Our data indicate, however, that *cis*-(Z)-flupentixol is less effective at blocking *Am*DOP1 receptors than *Am*DOP2 receptors, a result that is consistent with earlier studies [@pone.0026809-Mustard1], [@pone.0026809-Mustard2]. In combination these results suggest the *in vivo* effects of *cis*-(Z)-flupentixol treatment in insects are complex, not confined to dopaminergic signaling and potentially, species specific.

Spiperone {#s3e}
---------

Consistent with earlier studies on honey bee dopamine receptors [@pone.0026809-Blenau1], [@pone.0026809-Mustard2] we found spiperone to be an effective antagonist at both of the honey bee D1-like dopamine receptors, *Am*DOP1 ([Figure 7](#pone-0026809-g007){ref-type="fig"}) and *Am*DOP2 ([Figure 4B](#pone-0026809-g004){ref-type="fig"}). Interestingly, spiperone also acts as an antagonist at the honey bee octopamine receptor, *Am*OA1 ([Figure 5B](#pone-0026809-g005){ref-type="fig"}), but is not an effective blocker of the D2-like dopamine receptor, *Am*DOP3 ([Figure 7](#pone-0026809-g007){ref-type="fig"}). This is consistent with studies of DA receptors in *Drosophila*, where spiperone has been reported to be an antagonist of *Drosophila* D1-like DA receptors, *Dm*Dop1 [@pone.0026809-Sugamori1] and DAMB [@pone.0026809-Han1], but not the *Drosophila* D2-like receptor, DD2R [@pone.0026809-Hearn1]. These results are quite different to those reported for vertebrate DA receptors as in vertebrates, spiperone acts as a selective D2-like DA receptor blocker [@pone.0026809-Missale1].

Mianserin and epinastine {#s3f}
------------------------

Mianserin has previously been found to be an antagonist of three *Drosophila* 'β-adrenergic-like' OA receptors [@pone.0026809-Maqueira1], and the silkworm α-adrenergic-like OA receptor, *Bm*OAR [@pone.0026809-Ohtani1]. Mianserin has also been shown to have a significant affinity for the *Drosophila* tyramine receptor, *Dm*TyrR [@pone.0026809-Enan1], and in *C. elegans*, this antagonist is reported to block the serotonin receptors, SER-3 and SER-4 [@pone.0026809-Petrascheck1]. In this study we found that mianserin blocked responses mediated via *Am*OA1, *Am*DOP2 and *Am*TYR1 receptors, and that epinastine was an effective antagonist not only of the honey bee OA receptor, AmOA1, but also the DA receptor, *Am*DOP2. Taken together, these results suggest that *in vivo* effects of treatment with either mianserin or epinastine are unlikely to be confined to octopaminergic targets, as has previously been suggested [@pone.0026809-Roeder1], [@pone.0026809-Degen1]. Nonetheless, epinastine may prove useful in future studies for differentiating between responses mediated via *Am*DOP1 and *Am*DOP2, as *Am*DOP2 receptors are blocked very effectively by this antagonist, whereas *Am*DOP1 receptors are not. *Am*DOP2 and *Am*OA1 share a hydrophilic residue prior to TMV (E201 and N243 respectively, yellow alignment, [Figure 8](#pone-0026809-g008){ref-type="fig"}). In the corresponding position (L188) *Am*DOP1 has a leucine residue. This difference may help to explain the activity of epinastine at *Am*DOP2 and *Am*OA1 but not *Am*DOP1 as in human H1 receptors, the corresponding position (D186) has been shown to be important for histamine binding [@pone.0026809-Gantz1]. Interestingly however, responses mediated via AmTYR1, which possesses a hydrophilic but positively charged amino acid at the position (R192), were not affected by epinastine.

*Amdop2* and *Amoa1*: immediate paralogs? {#s3g}
-----------------------------------------

Our results show that of the five receptors examined, *Am*DOP2 and *Am*OA1 are the most similar in terms of their functional properties and pharmacological profile. This evidence suggests to us that the evolutionary relationship between these two receptor types is most likely to be that of immediate paralogs, and that despite divergence in their native ligand specificities, invertebrate-type DA receptors and α-adrenergic-like OA receptors still display significant conservation in their functional properties. The results of this study highlight the need to identify antagonists that act selectively on specific invertebrate receptor types. The identification of such compounds would greatly assist studies exploring the *in vivo* function(s) of biogenic amine receptors in invertebrates.

Materials and Methods {#s4}
=====================

Materials {#s4a}
---------

Dopamine hydrochloride, DL-octopamine hydrochloride, *cis*-(Z)-flupenthixol dihydrochloride, spiperone, epinastine hydrochloride and mianserin hydrochloride were obtained from Sigma-Aldrich. Edelfosine (2-O-methyl-PAF C-18) was obtained from Cayman Chemical Company, Ann Arbor, U.S.A.

Heterologous expression of the honey bee receptor proteins {#s4b}
----------------------------------------------------------

HEK293 cells (Invitrogen) were maintained as adherent cultures at 37°C, 5% CO~2~ in phenol-red free DMEM/F12 medium containing 10% fetal calf serum (Invitrogen). For expression of the receptor proteins in HEK293 cells, expression plasmid constructs were transiently transfected into the cells using FuGene-HD reagent (Roche) in accordance with the manufacturer\'s instructions. Control cells transfected with pIB/V5-His-GW/LacZ for expression of the beta-galactosidase reporter protein indicated that transfection efficiency was \>95%.

The creation of plasmid expression constructs for *Am*DOP1, *Am*DOP2, *Am*DOP3 and *Am*OA1 has been described in detail elsewhere [@pone.0026809-Mustard2]. The expression construct for the *Am*TYR1 receptor was created by PCR amplification of the coding sequences of the *Amtyr1* cDNA [@pone.0026809-Blenau2] and insertion into the HindIII and XbaI site of pcDNA3.1(+) vector using the following primer sequences; forward -- GCACGAAGCTTGCCACCATGAACTCGAGCGGGGAATCAG; reverse -- GACTTCTAGATCAACGAATGCGCAACAACCGTCT.

Measurement of \[Ca^2+^\]~i~ levels for assaying receptor function {#s4c}
------------------------------------------------------------------

Exponentially growing HEK293 cells (Invitrogen) were dispensed at a density of 2×10^4^ cells per well in 96-well, black-walled, clear-bottomed tissue culture plates (Greiner Bio-One) and allowed to grow for 24 hours. The cells were transfected with the desired honey bee receptor expression construct. Transfected cells were maintained for a further 24 hours at 37°C prior to assaying for receptor function. Intracellular Ca^2+^ levels were assayed by preloading the cells with Fluo-4 NW reporter dye dissolved in Hank\'s buffer in accordance with the manufacturer\'s instructions (Invitrogen). The fluorescence signal (excitation 480 nm, emission 520 nM) of individual wells was detected using a BMG Labtech Fluostar Omega microplate instrument. Amines were prepared immediately prior to use in Hanks buffer, and a 2 ul volume was introduced into test wells using onboard injectors. Treatment concentrations indicated in figure legends represent the final concentration of amine in the test well. Wells were monitored for fluorescent signal immediately prior to treatment to establish the baseline fluorescence (F~b~) and for 50 seconds post agonist injection to record changes in fluorescence (ΔF) at 0.24 second intervals. Amines added to test wells remained in the medium throughout the post-injection recording period.

Indirect measurement of intracellular cAMP levels for assaying receptor function {#s4d}
--------------------------------------------------------------------------------

Receptor coupling to intracellular cAMP signaling was assessed using a CRE-luciferase reporter as detailed previously [@pone.0026809-Mustard2]. In brief, HEK293 cells were co-transfected with the desired honey bee receptor expression construct together with the pGL4.29\[luc2P/CRE/Hygro\] reporter construct (Promega) and grown for a further 24 hours. The amount of *Am*DOP1 expression construct used for transfections was reduced to 1/10^th^ of the concentration used in earlier studies [@pone.0026809-Mustard2], because high-level expression of this constitutively active receptor [@pone.0026809-Baldauf1] was found to swamp the capacity of the reporter system [@pone.0026809-Hill1]. Cells were then incubated for 3 hours in serum-free growth medium containing the test treatments detailed in figure legends, and then immediately assayed for luciferase enzyme activity. Duplicate measurements were determined for each test treatment examined in the performance of independent trials. All *in vitro* expression work was conducted under approvals issued by the University of Otago Institutional Biological Safety Committee.

Sequence alignment and homology modelling {#s4e}
-----------------------------------------

The sequence alignment was initially carried out using T-coffee and then manually adjusted in a similar fashion to that described elsewhere [@pone.0026809-Bissantz1]. Models were generated using Modeller9v7 [@pone.0026809-Fiser1] using the human beta-adrenergic structure (pdb2rh1) as a template. The models with the lowest objective function were selected for further analysis. Docking experiments were carried out using Gold 4.1 [@pone.0026809-Jones1] to dock the epinastine into the binding site of the human histamine receptor. Both isomers of epinastine were used in the docking calculations and were downloaded from the Cambridge Crystallographic Data Centre (ID: CALQUC: *R*, CALRAJ; *S*).

**Competing Interests:**The authors have declared that no competing interests exist.

**Funding:**This research was supported by a grant from the Royal Society of New Zealand Marsden Fund (UOO0615, <http://marsden.rsnz.org>). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[^1]: Conceived and designed the experiments: KTB ARM. Performed the experiments: KTB. Analyzed the data: KTB JT. Contributed reagents/materials/analysis tools: JT. Wrote the paper: KTB ARM.
